Skip to main content
Springer Nature Link
Account

Table 5 Plasma concentrations of oxidative stress biomarkers (fructosamine, AGE, sRAGE and 8-isoprostanes) at weeks 0, 6, 12 of the intervention

From: No evidence of differential impact of sunflower and rapeseed oil on biomarkers of coronary artery disease or chronic kidney disease in healthy adults with overweight and obesity: result from a randomised control trial

 

Rapeseed oil

Sunflower oil

Control

Pmeas1

Pchange2

Concentration

ΔChange

Concentration

ΔChange

Concentration

ΔChange

Fructosamine (mM)

 Baseline

0.5 (0.4–0.6)

–

0.4 (0.4–0.5)

–

0.4 (0.3–0.5)

–

0.26

–

 Week 6

0.5 (0.4–0.5)

0.0 (− 0.1 to 0.0)

0.4 (0.3–0.5)

0.0 (− 0.1 to 0.0)

0.4 (0.4–0.6)

0.0 (0.0 to 0.1)

0.18

0.20

 Week 12

0.5 (0.4–0.5)

0.0 (− 0.1 to 0.1)

0.4 (0.4–0.5)

0.0 (− 0.1 to 0.1)

0.5 (0.4–0.5)

0.0 (0.0 to 0.1)

0.45

0.72

AGE (AU)

 Baseline

202.8 (164.7–286.9)

–

181.0 (143.5–215.2)

–

201.6 (159.9–239.6)

–

0.46

–

 Week 6

191.9 (170.4–248.1)

− 11.6 (− 50.7 to 25.9)

192.1 (159.8–227.8)

7.5 (− 21.5 to 28.5)

198.2 (172.7–221.9)

1.5 (− 36.3 to 43.1)

0.80

0.66

 Week 12

245.0 (210.8–315.7)

12.8 (− 32.5 to 117.5)

200.7 (147.9–214.9)

− 2.7 (− 36.3 to 19.7)

214.1 (181.3–279.6)

− 1 (− 38.9 to 40.3)

0.17

0.60

sRAGE (ng/ml)

 Baseline

34.5 (28–39.4)

–

43.0 (30.3–56.6)

–

36.0 (27.5–46.7)

–

0.30

-

 Week 6

28.9 (20.8–38.5)

− 2.4 (− 10.2 to 0.5)

36.9 (30.8–46.8)

− 0.4 (− 26.4 to 12.5)

30.2 (25.9–42.5)

− 0.4 (− 7.9 to 3.3)

0.13

0.71

 Week 12

25.9 (20.5–34.8)

− 0.9 (− 9.7 to 2.9)

28.1 (25.6–50.2)

− 1.2 (− 19.3 to 6.3)

26.4 (22.9–36.7)

− 2.4 (− 15.2 to 0.8)

0.66

0.93

8-Isoprostanes (pg/mg creatinine)

 Baseline

1101.5 (640.4–1416.4)

–

1239.3 (1023.1–1613.7)

–

1027.1 (776.2–1341.7)

–

0.27

–

 Week 6

1063.1 (811.7–1298.4)

− 138.9 (− 272.8 to 289.0)

978.31 (637.3–1415.7)

− 235.6 (− 557 to 114.6)

958.1 (773.3–1334.1)

23.3 (− 201.9 to 250.7)

0.97

0.11

 Week 12

971.8 (731.3–1378.1)

60.1 (− 271.8 to 373.6)

1488.6 (1108.3–1902.0)

− 84.0 (− 311.3 to 253.2)

888.0 (754.8–1071.8)

31.8 (− 289.2 to 220.7)

0.03

0.68

  1. Data are presented as medians (IQR)
  2. 1Pmeas: Kruskal–Wallis tested differences between groups at baseline. One-way ANCOVA tested differences between groups at weeks 6 and 12, after adjusting for baseline values
  3. 2Pchange: One-way ANOVA tested differences between groups in concentration changes from baseline at weeks 6 and 12. Friedman’s two-way analysis of variance was used to assess differences within groups. Plasma samples were missing from 10 participants at baseline (4 RO, 3 SO, 3 control), 14 participants at week 6 (5 RO, 5 SO, 4 control) and 10 participants at week 12 (4 RO, 4 SO, 2 control). *Indicates a significant difference from baseline, within group (p < 0.05; none in this table)
Back to article page